Not recruitingISRCTN25479460

Atomoxetine for Attention-deficit hyperActivity disorder Symptoms in children with pervasive developmental disorders: a pilot study

Research studyAges 6–17NetherlandsADHD

The study in practice

Understand this study

Listed age limits: 6 years to 17 years.

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Study start dateNot clearly listed

Recruitment status: Not recruiting
Enrollment listed in the registry: Not clearly listed
Sponsor: Accare (The Netherlands)
Sponsor type: Unknown or unclear
Study type: Other
Intervention type: Other / unclear
Study phase: Not clearly listed
Locations: Netherlands
Age range: From 6 Years to 17 Years
Official registry ID: ISRCTN25479460
Official title: Show the full official title
Atomoxetine for Attention-deficit hyperActivity disorder Symptoms in children with pervasive developmental disorders: a pilot study

This record does not confirm open recruitment. We can help you understand it and explore other studies.

Study ID: ISRCTN25479460. We help you review the study, but cannot decide medical eligibility.

Not recruiting

Netherlands

A listed location does not confirm current availability.

FAQ

Who is behind this study?

The study sponsor is Accare (The Netherlands).

Who can participate?

Listed age limits: 6 years to 17 years.

Is this study still recruiting?

The registry lists this study as not recruiting.

Explore other studies

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.